Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

49P - Exploiting multi-omic integrated data from DC-vaccinated melanoma patients for the generation of an advanced adoptive T cell therapy

Date

08 Dec 2022

Session

Poster Display

Presenters

Jenny Bulgarelli

Citation

Annals of Oncology (2022) 16 (suppl_1): 100101-100101. 10.1016/iotech/iotech100101

Authors

J. Bulgarelli1, M. Tazzari2, S. Carloni2, S. Pignatta1, M.T. Bochicchio1, M. Bocchini1, D. Angeli3, M. Tebaldi3, A.M. Granato1, C. Piccinini1, E. Pancisi2, F. De Rosa2, V. Ancarani2, F. Limarzi4, M. Petrini2, L. Ridolfi1

Author affiliations

  • 1 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola/IT
  • 2 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 - Meldola/IT
  • 3 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola/IT
  • 4 Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 49P

Background

Dendritic Cells (DCs) account for the best adaptive immune stimulators promoting their usage as advanced therapy medicinal products (ATMP). Despite the well tolerated profile and the ability to induce anti-tumor immunity, DC vaccine has nowadays failed to translate into prolonged long-term clinical benefit, requiring an update of its therapeutic application.

Methods

We conducted a retrospective study correlating clinical and multiple biologic data with the aim to define biomarkers of DC vaccine clinical activity and to exploit its capacity to expand peripheral autologous tumor-specific effector cells. Immunohistochemistry on pre and post FFPE samples, proteomic analysis on plasma and tumor homogenate, multiparametric flow cytometry on the starting apheresis and on DCs, RNAseq and scRNAseq on peripheral monocytes and manufactured DCs respectively, were applied.

Results

Analysis of post-vaccine biopsies highlighted the vaccine ability to induce intratumoral CD8 up-regulation (p=0.0195). The presence of multiple checkpoint molecules was a common denominator of our ATMP (PD-L1 90,1%-98,9%; PD-L2 94,9%-%99,5; VISTA 21,9%-%39,3; TIM-3 17%-59,4%; B7-H3 86,3%-98,8%). Intriguingly, high dimensional analysis of the DC final product revealed the coexistence of B cell clusters (CD19, MS4A1), higher (p=0.0286) in patients displaying clinical response. Of note, GMPc DCs induced a sustained expression of CD137 in co-cultured CD8+ T cells, and anti-PD1 addition enhanced the fraction of CD137+ T cells.

Conclusions

In vivo mechanisms of adaptive immune resistance (e.g. tumoral PDL1 upregulation p=0.0353) as well as the observed expression of checkpoint molecules by our ATMP support the clinical investigation of DC/ICI combination. The association of B cells with tumor response has to be deepened and the B cell frequency assessed also in pretreatment blood samples. Of note, the expansion of bona fide antigen-reactive CD137+ T cells resulting from the designed autologous DC ex vivo platform could translate into the manufacturing of a novel GMPc T cell product.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.